Smoking in the USA: 11 Questions on the Latest Numbers

Primary Viewpoints: Immunizations with Dr Steven P. Furr

Cebranopadol developer Tris Pharma expects to submit an NDA to the FDA for the dual-NMR agonist to treat moderate-to-severe acute pain later this year.

Keith A. Reynolds

October 1st 2024

Tris Pharma's Cebranopadol Shows Low Potential for Misuse in Intranasal Human Abuse Potential Study

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Steven P. Furr, former president of the American Academy of Family Physicians.

Infectious Disease & Primary Care: A Conversation with IDWeek 2023 Chair

The novel dual NMR agonist was scored significantly less "likable" when crushed and taken intranasally compared with oxycodone, the company reported.

October 25th 2023

FDA Approves New Indication for Semaglutide (Ozempic) to Lower Kidney Risks in Type 2 Diabetes, CKD

Listen to our latest podcast episode with Heather Yun, MD, for details on emerging pathogens, the role of primary care clinicians in the effort to rein in antimicrobial resistance, and more.

January 28th 2025

Alzheimer Assessment Update: Alzheimer's Association Publishes New Appropriate Use Criteria for Amyloid and Tau PET

This newest approval established Ozempic as the most broadly indicted GLP-1 RA in its class.

Dementia Assessment Update: Alzheimer's Association Publishes New Appropriate Use Criteria for Amyloid and Tau PET

January 28th 2025

Investigational Nonopioid Cebranopadol Meets Primary Endpoint in Pivotal Phase 3 ALLEVIATE-1 Clinical Trial

Related Content

Primary Viewpoints: Immunizations with Dr Steven P. Furr

Cebranopadol developer Tris Pharma expects to submit an NDA to the FDA for the dual-NMR agonist to treat moderate-to-severe acute pain later this year.

Keith A. Reynolds

October 1st 2024

Tris Pharma's Cebranopadol Shows Low Potential for Misuse in Intranasal Human Abuse Potential Study

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Steven P. Furr, former president of the American Academy of Family Physicians.

Infectious Disease & Primary Care: A Conversation with IDWeek 2023 Chair

The novel dual NMR agonist was scored significantly less "likable" when crushed and taken intranasally compared with oxycodone, the company reported.

October 25th 2023

FDA Approves New Indication for Semaglutide (Ozempic) to Lower Kidney Risks in Type 2 Diabetes, CKD

Listen to our latest podcast episode with Heather Yun, MD, for details on emerging pathogens, the role of primary care clinicians in the effort to rein in antimicrobial resistance, and more.

January 28th 2025